COSMED Announces Acquisition of Innovision Technology to Expand Product Portfolio and Presence in the Nordic Markets.

COSMED headquartered in Rome, Italy, leading manufacturer of Metabolic and Body composition technologies, has acquired assets of Innovision ApS, a Danish Company with significant know-how and expertise in the design of products for Hemodynamic (Cardiac Output), Ventilation Heterogeneity (Lung Clearance Index) and Metabolic measurements (VO2Max).

COSMED is glad to announce the U.S. Food and Drug Administration (FDA) clearance of Q-NRG+ and Q-NRG, a metabolic monitoring device utilizing Indirect Calorimetry (IC) technology intended for the measurement of Resting Energy Expenditure (REE) in patients who are mechanically ventilated or spontaneously breathing.

During these exceptional times, we would like to inform you that COSMED is adapting to the COVID-19 situation with diligence and is trying to face this big challenge with determination.

We wanted to take a moment to share with our customers, partners and communities how COSMED is responding to this evolving situation.

COSMED Srl, a worldwide leader in the design of metabolic systems for clinical and human performance applications and Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, today announced an agreement to commercialize Q-NRG+, a metabolic monitoring device utilizing indirect calorimetry technology.

Rome (Italy) - March 2018 - COSMED, world-wide leader in the design of metabolic systems for clinical and human performance applications, announced today the release of a new product line of metabolic monitors for quick, accurate, intuitive and affordable indirect calorimetry.